These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

918 related articles for article (PubMed ID: 33721704)

  • 21. Impact of performance status on non-small-cell lung cancer patients with a PD-L1 tumour proportion score ≥50% treated with front-line pembrolizumab.
    Friedlaender A; Metro G; Signorelli D; Gili A; Economopoulou P; Roila F; Banna G; De Toma A; Camerini A; Christopoulou A; Lo Russo G; Banini M; Galetta D; Jimenez B; Collazo-Lorduy A; Calles A; Baxevanos P; Linardou H; Kosmidis P; Mountzios G; Garassino MC; Addeo A
    Acta Oncol; 2020 Sep; 59(9):1058-1063. PubMed ID: 32762415
    [No Abstract]   [Full Text] [Related]  

  • 22. Pretreatment Glasgow prognostic score predicts survival among patients with high PD-L1 expression administered first-line pembrolizumab monotherapy for non-small cell lung cancer.
    Imai H; Kishikawa T; Minemura H; Yamada Y; Ibe T; Yamaguchi O; Mouri A; Hamamoto Y; Kanazawa K; Kasai T; Kaira K; Kaburagi T; Minato K; Kobayashi K; Kagamu H
    Cancer Med; 2021 Oct; 10(20):6971-6984. PubMed ID: 34414673
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Real-world first-line treatment with pembrolizumab for non-small cell lung carcinoma with high PD-L1 expression: Updated analysis.
    Ikezawa Y; Morita R; Mizugaki H; Tateishi K; Yokoo K; Sumi T; Kikuchi H; Kitamura Y; Nakamura A; Kobayashi M; Aso M; Kimura N; Yoshiike F; Megumi F; Tanaka H; Sekikawa M; Hachiya T; Nakamura K; Hommura F; Sukoh N; Ito K; Kikuchi T; Agatsuma T; Yokouchi H
    Cancer Med; 2024 Jul; 13(14):e70036. PubMed ID: 39030894
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Real-World Outcomes of Stage IV NSCLC with PD-L1 ≥ 50% Treated with First-Line Pembrolizumab: Uptake of Second-Line Systemic Therapy.
    Rittberg R; Leung B; Shokoohi A; Pender A; Wong S; Al-Hashami Z; Wang Y; Ho C
    Curr Oncol; 2023 May; 30(6):5299-5308. PubMed ID: 37366885
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Completion of Pembrolizumab in Advanced Non-Small Cell Lung Cancer-Real World Outcomes After Two Years of Therapy (COPILOT).
    Fantoni A; Warburton L; Solomon B; Alexander M; Maddula M; Brown LJ; da Silva IP; Nagrial A; Abu Al-Hial F; Itchins M; Pavlakis N; Bowyer S
    Clin Lung Cancer; 2024 Jul; 25(5):449-459. PubMed ID: 38705835
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Outcomes of first-line pembrolizumab monotherapy for PD-L1-positive (TPS ≥50%) metastatic NSCLC at US oncology practices.
    Velcheti V; Chandwani S; Chen X; Pietanza MC; Piperdi B; Burke T
    Immunotherapy; 2019 Dec; 11(18):1541-1554. PubMed ID: 31774363
    [No Abstract]   [Full Text] [Related]  

  • 27. First-line pembrolizumab monotherapy for metastatic PD-L1-positive NSCLC: real-world analysis of time on treatment.
    Velcheti V; Chandwani S; Chen X; Pietanza MC; Burke T
    Immunotherapy; 2019 Jul; 11(10):889-901. PubMed ID: 31181973
    [No Abstract]   [Full Text] [Related]  

  • 28. Clinical factors associated with shorter durable response, and patterns of acquired resistance to first-line pembrolizumab monotherapy in PD-L1-positive non-small-cell lung cancer patients: a retrospective multicenter study.
    Hosoya K; Fujimoto D; Morimoto T; Kumagai T; Tamiya A; Taniguchi Y; Yokoyama T; Ishida T; Matsumoto H; Hirano K; Kominami R; Tomii K; Suzuki H; Hirashima T; Tanaka S; Uchida J; Morita M; Kanazu M; Mori M; Nagata K; Fukuda I; Tamiya M
    BMC Cancer; 2021 Apr; 21(1):346. PubMed ID: 33794809
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Blood serum amyloid A as potential biomarker of pembrolizumab efficacy for patients affected by advanced non-small cell lung cancer overexpressing PD-L1: results of the exploratory "FoRECATT" study.
    Di Noia V; D'Argento E; Pilotto S; Vita E; Ferrara MG; Damiano P; Ribelli M; Cannella A; Virtuoso A; Fattorossi A; Ceresoli GL; Milella M; Beretta GD; Tortora G; Bria E
    Cancer Immunol Immunother; 2021 Jun; 70(6):1583-1592. PubMed ID: 33231726
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Upfront pembrolizumab as an effective treatment start in patients with PD-L1 ≥ 50% non-oncogene addicted non-small cell lung cancer and asymptomatic brain metastases: an exploratory analysis.
    Metro G; Gili A; Signorelli D; De Toma A; Garaffa M; Galetta D; Economopoulou P; Friedlaender A; Jimenez B; Collazo-Lorduy A; Addeo A; Chiarini P; Costa C; Mountzios G; Roila F
    Clin Transl Oncol; 2021 Sep; 23(9):1818-1826. PubMed ID: 33728869
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Therapy Line and Associated Predictors of Response to PD-1/PD-L1-Inhibitor Monotherapy in Advanced Non-small-Cell Lung Cancer: A Retrospective Bi-centric Cohort Study.
    Lang D; Huemer F; Rinnerthaler G; Horner A; Wass R; Brehm E; Akbari K; Granitz M; Hutarew G; Kaiser B; Greil R; Lamprecht B
    Target Oncol; 2019 Dec; 14(6):707-717. PubMed ID: 31654203
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Baseline BMI and BMI variation during first line pembrolizumab in NSCLC patients with a PD-L1 expression ≥ 50%: a multicenter study with external validation.
    Cortellini A; Ricciuti B; Tiseo M; Bria E; Banna GL; Aerts JG; Barbieri F; Giusti R; Cortinovis DL; Migliorino MR; Catino A; Passiglia F; Torniai M; Morabito A; Genova C; Mazzoni F; Di Noia V; Signorelli D; Gelibter A; Occhipinti MA; Rastelli F; Chiari R; Rocco D; Inno A; De Tursi M; Di Marino P; Mansueto G; Zoratto F; Grossi F; Filetti M; Pizzutilo P; Russano M; Citarella F; Cantini L; Targato G; Nigro O; Ferrara MG; Buti S; Scodes S; Landi L; Guaitoli G; Della Gravara L; Tabbò F; Ricciardi S; De Toma A; Friedlaender A; Petrelli F; Addeo A; Porzio G; Ficorella C
    J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33077515
    [TBL] [Abstract][Full Text] [Related]  

  • 33. KEYNOTE-025: Phase 1b study of pembrolizumab in Japanese patients with previously treated programmed death ligand 1-positive advanced non-small-cell lung cancer.
    Nishio M; Takahashi T; Yoshioka H; Nakagawa K; Fukuhara T; Yamada K; Ichiki M; Tanaka H; Seto T; Sakai H; Kasahara K; Satouchi M; Han SR; Noguchi K; Shimamoto T; Kato T
    Cancer Sci; 2019 Mar; 110(3):1012-1020. PubMed ID: 30618179
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical outcomes of pembrolizumab therapy in advanced-NSCLC patients with poor performance status (≥3) and high PD-L1 expression (TPS ≥50%): A case series.
    Inaba-Higashiyama R; Yoshida T; Jo H; Shirasawa M; Motoi N; Ohe Y
    Thorac Cancer; 2020 Dec; 11(12):3618-3621. PubMed ID: 33085191
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immune checkpoint inhibitors, alone or in combination with chemotherapy, as first-line treatment for advanced non-small cell lung cancer. A systematic review and network meta-analysis.
    Dafni U; Tsourti Z; Vervita K; Peters S
    Lung Cancer; 2019 Aug; 134():127-140. PubMed ID: 31319971
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer.
    Gandhi L; Rodríguez-Abreu D; Gadgeel S; Esteban E; Felip E; De Angelis F; Domine M; Clingan P; Hochmair MJ; Powell SF; Cheng SY; Bischoff HG; Peled N; Grossi F; Jennens RR; Reck M; Hui R; Garon EB; Boyer M; Rubio-Viqueira B; Novello S; Kurata T; Gray JE; Vida J; Wei Z; Yang J; Raftopoulos H; Pietanza MC; Garassino MC;
    N Engl J Med; 2018 May; 378(22):2078-2092. PubMed ID: 29658856
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Q-TWiST Analysis to Assess Benefit-Risk of Pembrolizumab in Patients with PD-L1-Positive Advanced or Metastatic Non-small Cell Lung Cancer.
    Huang M; Pietanza MC; Samkari A; Pellissier J; Burke T; Chandwani S; Kong F; Pickard AS
    Pharmacoeconomics; 2019 Jan; 37(1):105-116. PubMed ID: 30515719
    [TBL] [Abstract][Full Text] [Related]  

  • 38. First-line pembrolizumab with or without platinum doublet chemotherapy in non-small-cell lung cancer patients with PD-L1 expression ≥50.
    Descourt R; Chouaid C; Pérol M; Besse B; Greillier L; Bylicki O; Ricordel C; Guisier F; Gervais R; Schott R; Auliac JB; Robinet G; Decroisette C
    Future Oncol; 2021 Aug; 17(23):3007-3016. PubMed ID: 34156285
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The efficacy outcomes in non-small cell lung cancer patients treated with PD axis inhibitor agents - a population-based study of the Vojvodina region.
    Lalić N; Bojović M; Bursać D; Bokan D; Čeriman Krstić V; Kuhajda I; Parapid B; Tomić S; Šipka A
    Pathol Oncol Res; 2024; 30():1611717. PubMed ID: 39071547
    [No Abstract]   [Full Text] [Related]  

  • 40. First-line treatment for patients with advanced non-small cell lung carcinoma and high PD-L1 expression: pembrolizumab or pembrolizumab plus chemotherapy.
    Zhou Y; Lin Z; Zhang X; Chen C; Zhao H; Hong S; Zhang L
    J Immunother Cancer; 2019 May; 7(1):120. PubMed ID: 31053172
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 46.